Centyl með kaliumklorid Filmuhúðuð tafla 2,5 mg+573 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

centyl með kaliumklorid filmuhúðuð tafla 2,5 mg+573 mg

karo pharma ab* - bendroflumethiazidum inn; kalii chloridum - filmuhúðuð tafla - 2,5 mg+573 mg

Centyl mite með kaliumklorid Filmuhúðuð tafla 1,25 mg/573 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

centyl mite með kaliumklorid filmuhúðuð tafla 1,25 mg/573 mg

karo pharma ab* - kalii chloridum; bendroflumethiazidum inn - filmuhúðuð tafla - 1,25 mg/573 mg

Darazíð Tafla 20 mg/12,5 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

darazíð tafla 20 mg/12,5 mg

actavis group ptc ehf. - enalaprilum maleat; hydrochlorothiazidum inn - tafla - 20 mg/12,5 mg

Mekinist Evrópusambandið - íslenska - EMA (European Medicines Agency)

mekinist

novartis europharm limited - trametinib - melanoma - Æxlishemjandi lyf - melanomatrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation (see sections 4. 4 og 5. trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior braf inhibitor therapy (see section 5. adjuvant treatment of melanomatrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with a braf v600 mutation, following complete resection. ekki lítinn klefa lungnakrabbamein (nsclc)trametinib ásamt dabrafenib er ætlað fyrir meðferð fullorðinn sjúklinga með langt ekki lítið klefi lungnakrabbamein með meÐferÐ v600 stökkbreytingu.

Koselugo Evrópusambandið - íslenska - EMA (European Medicines Agency)

koselugo

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - Æxlishemjandi lyf - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.